+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infectious Diseases In-Vitro Diagnostics Market - Global Forecast 2026-2032- Product Image
Infectious Diseases In-Vitro Diagnostics Market - Global Forecast 2026-2032- Product Image
Sale

Infectious Diseases In-Vitro Diagnostics Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337418
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Infectious Diseases In-Vitro Diagnostics Market is projected to reach USD 28.24 Billion in 2026. It is expected to continue growing at a CAGR of 6.35%, reaching USD 40.98 Billion by 2032.

Infectious diseases in-vitro diagnostics (IVD) sit at the center of global health security, enabling rapid identification of respiratory viruses, antimicrobial-resistant organisms, sexually transmitted infections, tuberculosis, HIV, hepatitis, gastrointestinal pathogens, and emerging zoonotic threats. Demand is supported by the World Health Organization’s continued focus on surveillance, the CDC’s emphasis on diagnostic stewardship, and the persistent clinical need to distinguish bacterial, viral, fungal, and parasitic infections quickly and accurately.

The market is increasingly shaped by molecular diagnostics, immunoassays, syndromic panels, point-of-care testing, digital microbiology, and laboratory automation. Procurement decisions are moving beyond test sensitivity and specificity to include turnaround time, reimbursement alignment, workflow integration, quality controls, data interoperability, and capacity to support outbreak preparedness across centralized labs, hospitals, urgent care networks, and decentralized community settings.

Transformative Shifts in the Diagnostic Landscape

The infectious diseases IVD landscape is shifting from single-pathogen, centralized testing toward connected diagnostic ecosystems that combine high-throughput laboratory platforms with rapid near-patient testing. COVID-19 accelerated acceptance of molecular testing, self-collection, decentralized sampling, and public-health reporting infrastructure, creating durable expectations for faster access and scalable testing during seasonal surges.

Healthcare systems are also prioritizing antimicrobial resistance surveillance, sepsis diagnostics, tuberculosis testing, and multiplex respiratory panels as clinicians seek earlier targeted therapy. At the same time, regulatory scrutiny, supply-chain resilience, laboratory workforce shortages, and payer pressure are influencing product design. Manufacturers that can deliver clinically actionable results, automated workflows, cybersecurity-ready connectivity, and evidence of improved patient outcomes are better positioned in this evolving IVD market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force in infectious diseases diagnostics by improving assay development, image interpretation, epidemiological modeling, workflow triage, and result interpretation. AI-enabled algorithms can support digital pathology, Gram stain review, antimicrobial susceptibility prediction, syndromic decision support, and outbreak signal detection when validated against high-quality clinical datasets and governed by transparent quality systems.

The impact is strongest when AI is embedded into laboratory information systems, electronic health records, and surveillance networks rather than treated as a standalone tool. However, adoption depends on data representativeness, regulatory validation, explainability, cybersecurity, privacy safeguards, and clinician trust. Organizations that combine AI with rigorous clinical performance evidence can improve speed, consistency, and population-level infectious disease intelligence.

Key Regional Insights: Global IVD Adoption Patterns

Asia-Pacific is a high-priority region for infectious diseases IVD due to large populations, expanding hospital infrastructure, tuberculosis and hepatitis screening programs, and rising molecular testing capacity in China, India, Japan, South Korea, Australia, and ASEAN markets. North America remains a technology and reimbursement leader, supported by strong clinical laboratory networks, FDA oversight, CDC surveillance priorities, and sustained demand for respiratory, STI, sepsis, healthcare-associated infection, and antimicrobial resistance testing.

Europe benefits from harmonized quality expectations under the EU IVDR, strong public-health laboratories, and broad antimicrobial stewardship programs, while Latin America is expanding access through public procurement, private diagnostics chains, and infectious disease screening initiatives in Brazil and Mexico. The Middle East is investing in advanced hospital diagnostics and health-system modernization, particularly across GCC countries, while Africa’s priorities center on affordable point-of-care testing, HIV, malaria, tuberculosis, hepatitis, neglected tropical diseases, and outbreak surveillance supported by national and international health programs.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are expanding infectious diseases IVD capacity through hospital modernization, dengue and tuberculosis testing, hepatitis screening, and stronger cross-border outbreak surveillance. The GCC is prioritizing premium hospital diagnostics, national screening initiatives, digital health integration, and laboratory automation as part of broader health transformation strategies. The European Union is reshaping supplier requirements through IVDR compliance, clinical evidence expectations, traceability, and post-market performance monitoring.

BRICS countries represent substantial diagnostic demand because of large patient populations, infectious disease burden, and growing domestic diagnostic manufacturing capabilities. G7 markets drive innovation, reimbursement evidence, laboratory quality standards, and advanced molecular adoption, while NATO-aligned health systems increasingly view diagnostics as part of biosecurity, preparedness, and resilient medical supply chains. Across these groups, successful IVD strategies align clinical utility with affordability, regulatory readiness, interoperability, and dependable supply.

Key Country Insights Across Major IVD Markets

The United States leads in advanced molecular platforms, multiplex respiratory testing, commercial laboratory scale, and rapid adoption of digital reporting, while Canada emphasizes quality-assured public health testing and equitable access across provinces. Mexico and Brazil are expanding infectious disease diagnostics through public programs, private laboratory networks, and screening initiatives for respiratory infections, HIV, hepatitis, tuberculosis, and vector-borne diseases. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature hospital systems with antimicrobial stewardship priorities, sepsis management, and EU IVDR-aligned quality expectations, while Russia maintains demand for tuberculosis, respiratory, hepatitis, and hospital infection testing.

China is rapidly scaling domestic IVD innovation and hospital laboratory capacity, India is expanding affordable molecular and point-of-care testing for tuberculosis, hepatitis, HIV, and respiratory infections, and Japan prioritizes high-quality automated diagnostics for hospitals and aging-care settings. Australia and South Korea stand out for strong surveillance infrastructure, advanced hospital laboratories, antimicrobial resistance monitoring, and early adoption of digital and molecular diagnostic technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that deliver clinically actionable results within the time window needed to influence treatment, isolation, and antimicrobial stewardship decisions. Product roadmaps should emphasize multiplex flexibility, sample-to-answer automation, connectivity with laboratory information systems, electronic health record compatibility, and evidence packages that demonstrate reduced length of stay, optimized antibiotic use, improved infection control, or stronger outbreak response.

Manufacturers should diversify supply chains for reagents, plastics, enzymes, controls, and instruments while building regulatory strategies tailored to FDA, EU IVDR, and high-priority emerging-market requirements. Commercial teams should segment customers by care setting, testing volume, reimbursement pathway, laboratory workforce capacity, and public-health need. Strategic partnerships with hospitals, reference laboratories, governments, and digital health providers can accelerate adoption and strengthen long-term market resilience.

Research Methodology and Evidence Framework

This executive summary is developed using a structured secondary-research approach grounded in publicly available, authoritative sources such as WHO, CDC, ECDC, FDA, OECD, World Bank, national health agencies, peer-reviewed literature, and regulatory guidance. The methodology evaluates disease burden, testing demand, regulatory dynamics, technology adoption, healthcare infrastructure, laboratory capacity, surveillance priorities, and procurement patterns across regions, groups, and key countries.

Insights are synthesized through triangulation of public-health priorities, laboratory workflow trends, reimbursement considerations, regulatory evidence requirements, and competitive technology signals. The analysis avoids unsupported claims and focuses on verifiable indicators, including surveillance needs, antimicrobial resistance priorities, molecular testing adoption, point-of-care expansion, quality-assurance requirements, and health-system investment patterns relevant to infectious diseases IVD decision-making.

Conclusion: Diagnostics as a Core Health Security Asset

Infectious diseases IVD is evolving from episodic testing into a strategic pillar of precision care, antimicrobial stewardship, infection prevention, and public-health preparedness. The most competitive organizations will combine reliable assay performance with faster workflows, digital connectivity, scalable manufacturing, resilient supply chains, and clear clinical utility.

As health systems face respiratory virus seasonality, antimicrobial resistance, endemic infections, healthcare-associated infections, and emerging pathogens, demand will favor diagnostics that support earlier decisions and stronger surveillance. Organizations that align innovation with regulatory evidence, affordability, interoperability, and regional healthcare priorities can support sustainable growth while improving patient outcomes and population health security.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Infectious Diseases In-Vitro Diagnostics Market, by Product
7.1. Introduction
7.2. Instruments
7.2.1. Automated Culture Systems
7.2.2. Immunoassay Instruments
7.2.3. PCR Instruments
7.3. Reagents & Kits
7.3.1. Immunoassay Kits
7.3.2. Microbial Culture Media
7.3.3. PCR Reagents
7.4. Software & Services
7.4.1. Consulting Services
7.4.2. Data Management Software
7.4.3. Maintenance & Support Services
8. Infectious Diseases In-Vitro Diagnostics Market, by Technology
8.1. Introduction
8.2. Immunoassays
8.2.1. Chemiluminescence Immunoassay
8.2.2. Enzyme Linked Immunosorbent Assay
8.2.3. Fluorescence Immunoassay
8.2.4. Lateral Flow Assay
8.3. Microbiology Culture
8.4. Molecular Diagnostics
8.4.1. Isothermal Amplification
8.4.2. Next Generation Sequencing
8.4.3. Polymerase Chain Reaction
9. Infectious Diseases In-Vitro Diagnostics Market, by Pathogen
9.1. Introduction
9.2. Bacterial
9.2.1. Enterobacteriaceae
9.2.2. Mycobacterium Tuberculosis
9.2.3. Staphylococcus Aureus
9.3. Fungal
9.4. Parasitic
9.5. Viral
9.5.1. Hepatitis Virus
9.5.2. Human Immunodeficiency Virus
9.5.3. Influenza Virus
10. Infectious Diseases In-Vitro Diagnostics Market, by Application
10.1. Introduction
10.2. Diagnosis
10.3. Epidemiological Surveillance
10.4. Monitoring
10.5. Screening
11. Infectious Diseases In-Vitro Diagnostics Market, by End User
11.1. Introduction
11.2. Academic Research Institution
11.3. Clinic
11.4. Hospital
11.5. Laboratory
12. Infectious Diseases In-Vitro Diagnostics Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Infectious Diseases In-Vitro Diagnostics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Infectious Diseases In-Vitro Diagnostics Market, by Country
14.1. United States
14.2. Germany
14.3. China
14.4. United Kingdom
14.5. India
14.6. Japan
14.7. Russia
14.8. Brazil
14.9. Canada
14.10. Italy
14.11. Mexico
14.12. France
14.13. Spain
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Becton, Dickinson and Company
16.3. Bio-Rad Laboratories, Inc.
16.4. bioMérieux SA
16.5. Danaher Corporation
16.6. DiaSorin S.p.A
16.7. Epitope Diagnostics, Inc.
16.8. F. Hoffmann La-Roche Ltd.
16.9. Grifols, S.A.
16.10. Hologic, Inc.
16.11. Illumina, Inc.
16.12. InBios International, Inc.
16.13. Koninklijke Philips N.V.
16.14. Merck KGaA
16.15. Meril Life Sciences Pvt. Ltd.
16.16. OraSure Technologies, Inc.
16.17. Qiagen N.V.
16.18. Quest Diagnostics
16.19. Quidel Corporation
16.20. Siemens Healthineers AG
16.21. Sysmex Corporation
16.22. Thermo Fisher Scientific Inc.
16.23. Trinity Biotech PLC
16.24. Vela Diagnostics
List of Figures
FIGURE 1. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025 VS 2032 (%)
FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL AUTOMATED CULTURE SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL AUTOMATED CULTURE SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL AUTOMATED CULTURE SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL IMMUNOASSAY INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL IMMUNOASSAY INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL IMMUNOASSAY INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PCR INSTRUMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL MICROBIAL CULTURE MEDIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL MICROBIAL CULTURE MEDIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL MICROBIAL CULTURE MEDIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PCR REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PCR REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PCR REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CONSULTING SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CONSULTING SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CONSULTING SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL DATA MANAGEMENT SOFTWARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL DATA MANAGEMENT SOFTWARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL DATA MANAGEMENT SOFTWARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MAINTENANCE & SUPPORT SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MAINTENANCE & SUPPORT SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MAINTENANCE & SUPPORT SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL FLUORESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL MICROBIOLOGY CULTURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MICROBIOLOGY CULTURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MICROBIOLOGY CULTURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ENTEROBACTERIACEAE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ENTEROBACTERIACEAE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ENTEROBACTERIACEAE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL MYCOBACTERIUM TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL STAPHYLOCOCCUS AUREUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL STAPHYLOCOCCUS AUREUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL STAPHYLOCOCCUS AUREUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL FUNGAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL FUNGAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL FUNGAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL PARASITIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PARASITIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PARASITIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL VIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HEPATITIS VIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL HEPATITIS VIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HEPATITIS VIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL INFLUENZA VIRUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL DIAGNOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL DIAGNOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL EPIDEMIOLOGICAL SURVEILLANCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL EPIDEMIOLOGICAL SURVEILLANCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL EPIDEMIOLOGICAL SURVEILLANCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL ACADEMIC RESEARCH INSTITUTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL ACADEMIC RESEARCH INSTITUTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL ACADEMIC RESEARCH INSTITUTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL CLINIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL CLINIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL CLINIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL LABORATORY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL LABORATORY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL LABORATORY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 132. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 133. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 148. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 149. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 150. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 151. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 152. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 153. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 154. NORTH AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 159. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 160. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 161. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 162. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 163. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 164. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 165. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 166. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 167. LATIN AMERICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 170. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 171. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 172. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 173. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 174. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 175. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 176. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 177. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 178. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 179. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 180. EUROPE INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 181. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 182. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 183. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 184. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 185. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 186. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 187. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 188. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 189. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 190. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 191. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 192. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 193. MIDDLE EAST INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 195. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 196. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 197. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 198. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 199. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 200. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 201. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 202. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 203. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 204. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 205. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 206. AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 208. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 209. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 210. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 211. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 212. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 213. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 214. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 215. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 216. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 217. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 218. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 219. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 220. ASEAN INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 221. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 222. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 223. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 224. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 225. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 226. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 227. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 228. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 229. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 230. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 231. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 232. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 233. GCC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 235. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 236. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 237. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 238. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 239. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 240. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 241. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 242. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 243. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 244. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 248. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 249. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 250. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 251. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 252. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 253. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 254. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 255. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 256. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 257. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 258. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 259. BRICS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 260. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 261. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 262. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 263. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 264. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 265. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 266. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 267. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 268. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 269. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 270. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 271. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 272. G7 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 273. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 274. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 275. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 276. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 277. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 278. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 279. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 280. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 281. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 282. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 283. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 284. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 285. NATO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 286. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 287. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 288. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 289. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 290. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 291. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 292. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 293. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 294. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 295. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 296. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 297. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 298. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 299. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 301. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 302. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 303. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 304. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 305. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 306. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 307. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 308. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2017-2032 (USD MILLION)
TABLE 309. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2017-2032 (USD MILLION)
TABLE 310. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2017-2032 (USD MILLION)
TABLE 311. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 312. GERMANY INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 313. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 314. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 315. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2017-2032 (USD MILLION)
TABLE 316. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2017-2032 (USD MILLION)
TABLE 317. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2017-2032 (USD MILLION)
TABLE 318. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 319. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2017-2032 (USD MILLION)
TABLE 320. CHINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017

Companies Mentioned

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMérieux SA
  • Danaher Corporation
  • DiaSorin S.p.A
  • Epitope Diagnostics, Inc.
  • F. Hoffmann La-Roche Ltd.
  • Grifols, S.A.
  • Hologic, Inc.
  • Illumina, Inc.
  • InBios International, Inc.
  • Koninklijke Philips N.V.
  • Merck KGaA
  • Meril Life Sciences Pvt. Ltd.
  • OraSure Technologies, Inc.
  • Qiagen N.V.
  • Quest Diagnostics
  • Quidel Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • Vela Diagnostics

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 28.24 Billion
Forecasted Market Value ( USD ) by 2032 $ 40.98 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Infectious Disease In-vitro Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Infectious Disease In-vitro Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 199 Pages
  • Global
From
Infectious Disease in Vitro Diagnostics Market Report 2026 - Product Image

Infectious Disease in Vitro Diagnostics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Infectious Disease In Vitro Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Infectious Disease In Vitro Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 110 Pages
  • Global
From
Infectious Disease Diagnostic Market - Global Forecast 2026-2032 - Product Image

Infectious Disease Diagnostic Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Direct-From-Blood Pathogen Detection Global Market Report 2026 - Product Image

Direct-From-Blood Pathogen Detection Global Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.